DRTS Stock Forecast & Price Target

Alpha Tau Medical is a clinical-stage oncology therapeutics company with a unique technology that harnesses the therapeutic properties of alpha particles for localized radiation therapy. The company has active clinical programs targeting various tumor types and has recently completed enrollment in a pivotal trial for recurrent cutaneous squamous cell carcinoma, with topline data expected in late 2026. Financially, the company reported a net loss of $22.9 million in its 1Q26 financial results, but this was due to the remeasurement of warrants liability. The company has potential for future FDA pre-market approval and market penetration, though there are risks involved, such as failure in clinical trials or achieving commercial success. Based on their projected market value and estimated shares outstanding, this suggests a value of $15 per share, leading to a Buy rating and a 12-month price target of $15.

Alpha Tau Medical is currently facing significant financial risks as a result of its ongoing clinical trials and limited revenue sources. While recent results from the U.S. REGAIN GBM trial have been positive, the long-term success and profitability of the company are uncertain due to the competitive market for cancer therapies and the potential for adverse events with its Alpha DaRT technology. Additionally, the company's reliance on external funding to support its operations and the high cost of clinical trials may strain its financial resources in the future.